Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Krishna Kishore Sharma has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

    by Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller

    Macrocyclic peptides have emerged as a compelling class of therapeutics, combining the modularity and synthetic accessibility of small molecules with the high affinity and target selectivity of biologics. Their ability to engage challenging and traditionally “undruggable” protein targets—including protein–protein interactions and allosteric sites—has generated widespread interest. However, pharmacokinetic limitations such as poor oral bioavailability, metabolic instability, and low membrane permeability continue to hinder clinical translation. The strategic incorporation of unnatural amino acids (UAAs) has proven critical for overcoming these challenges, enabling fine‐tuning of key physicochemical and pharmacological properties. In this review, we highlight recent clinical advances—including motixafortide and zilucoplan—and examine how UAAs are deployed to optimize drug‐like characteristics across diverse therapeutic areas. We discuss emerging strategies, illustrative case studies, and design principles that collectively support the development of next‐generation macrocyclic peptide drugs.

  • Open Access

    Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

    by Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller

    Macrocyclic peptides have emerged as a compelling class of therapeutics, combining the modularity and synthetic accessibility of small molecules with the high affinity and target selectivity of biologics. Their ability to engage challenging and traditionally “undruggable” protein targets—including protein–protein interactions and allosteric sites—has generated widespread interest. However, pharmacokinetic limitations such as poor oral bioavailability, metabolic instability, and low membrane permeability continue to hinder clinical translation. The strategic incorporation of unnatural amino acids (UAAs) has proven critical for overcoming these challenges, enabling fine‐tuning of key physicochemical and pharmacological properties. In this review, we highlight recent clinical advances—including motixafortide and zilucoplan—and examine how UAAs are deployed to optimize drug‐like characteristics across diverse therapeutic areas. We discuss emerging strategies, illustrative case studies, and design principles that collectively support the development of next‐generation macrocyclic peptide drugs.


  • Open Access

    Amidine isosteric modification tunes proteolytic stability and activity

    by Jacob Byerly-Duke, Sarah M. Bernhard, Rida Ibrahim, Sayan Das, Krishna K. Sharma, Chinmaya Panda, Vincenzo Venditti, Tao Che, Brett VanVeller

    Site-selective amidine substitution transforms labile peptide bonds into protease-resistant isosteres while preserving receptor signaling, providing a minimal backbone-editing strategy to improve peptide stability.


  • Open Access

    A Versatile Strategy for Head-to-Tail Macrocyclization and Traceless Backbone Editing of Short Peptides

    by Brendan J. Wall, Udayan Chaudhury, Krishna K. Sharma, Vincenzo Venditti, Brett VanVeller

    The efficient synthesis of short, head-to-tail macrocyclic peptides remains a fundamental challenge in chemical biology and drug discovery, particularly for homochiral sequences lacking turn-inducing residues. We hypothesized that thioimidates─a dynamic, backbone-localized functional group with a near 1:1 cis/trans-isomeric equilibrium─could promote macrocyclization by biasing the formation of preorganized conformers while also enhancing peptide solubility. Herein, we demonstrate that incorporation of a single thioimidate dramatically improves the efficiency of macrocyclization, enabling high-yielding cyclizations of tetra- and pentapeptides that fail under conventional conditions. A mild Ag(I)-mediated protocol then converts the thioimidate to the native amide, allowing access to previously inaccessible macrocyclic peptides. Post cyclization, the thioimidate also serves as a versatile and traceless branch point for backbone editing, furnishing native and 18O-isotopically labeled amides, in addition to thioamides, amidines, and secondary amine pseudopeptides from a common precursor. These transformations expand the structural and functional diversity of macrocyclic peptides using readily implementable synthetic workflows that are compatible with SPPS, thereby positioning thioimidates as a powerful platform to access previously inaccessible cyclic peptide scaffolds.


  • Top Cited Papers

    Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery

    by Krishna K. Sharma, Komal Sharma, Kamya Rao, Anku Sharma, Gajanan K. Rathod, Shams Aaghaz, Naina Sehra, Rajesh Parmar, Brett VanVeller, Rahul Jain

    Peptides can operate as therapeutic agents that sit within a privileged space between small molecules and larger biologics. Despite examples of their potential to regulate receptors and modulate disease pathways, the development of peptides with drug-like properties remains a challenge. In the quest to optimize physicochemical parameters and improve target selectivity, unnatural amino acids (UAAs) have emerged as critical tools in peptide- and peptidomimetic-based drugs. The utility of UAAs is illustrated by clinically approved drugs such as methyldopa, baclofen, and gabapentin in addition to small drug molecules, for example, bortezomib and sitagliptin. In this Perspective, we outline the strategy and deployment of UAAs in FDA-approved drugs and their targets. We further describe the modulation of the physicochemical properties in peptides using UAAs. Finally, we elucidate how these improved pharmacological parameters and the role played by UAAs impact the progress of analogs in preclinical stages with an emphasis on the role played by UAAs.


  • Complementary Strategies for Installation of Thioimidates into Peptide Backbones

    by Jacob Byerly-Duke, Aaron Donovan, Emily A. O’bRien, Krishna K. Sharma, Rida Ibrahim, Levi M. Stanley, Brett VanVeller

    Thioimidates are a precursor and synthetic branch point to access either thioamide or amidine isosteres of the native amide (peptide bond). Previous syntheses of thioimidate-containing peptides were prone to side reactivity and required slow, cumbersome steps that were difficult to monitor. We describe a more efficient approach to directly couple thioimidates onto the growing peptide chain. This work also outlines optimal conditions for thioimidate formation on solid support and identifies potential off-target sites for alkylation that impact the choice of protecting group.


  • General Installation of (4H)-Imidazolone cis-Amide Bioisosteres Along the Peptide Backbone

    by Brendan J. Wall, Krishna K. Sharma, Emily A. O’brien, Aaron Donovan, Brett VanVeller

    Imidazolones represent an important class of heterocycles present in a wide range of pharmaceuticals, metabolites, and bioactive natural products and serve as the active chromophore in green fluorescent protein. Recently, imidazolones have received attention for their ability to act as a nonaromatic amide bond bioisotere which improves pharmacological properties. Herein, we present a tandem amidine installation and cyclization with an adjacent ester to yield (4H)-imidazolone products. Using amino acid building blocks, we can access the first examples of α-chiral imidazolones that have been previously inaccessible. Additionally, our method is amenable to on-resin installation which can be seamlessly integrated into existing solid-phase peptide synthesis protocols. Finally, we show that peptide imidazolones are potent cis-amide bond surrogates that preorganize linear peptides for head-to-tail macrocyclization. This work represents the first general approach to the backbone and side-chain insertion of imidazolone bioisosteres at various positions in linear and cyclic peptides.


  • Open Access

    General Installation of (4H)-Imidazolone cis-Amide Bioisosteres Along the Peptide Backbone

    by Brendan Wall, Emily O'BRien, Krishna Sharma, Aaron Donovan, Brett VanVeller

    Imidazolones represent an important class of heterocycles present in a wide-range of pharmaceuticals, metabolites, naturally-occurring bioactive natural products, and serve as the active chromophore in green fluorescent protein (GFP). Recently imidazolones have received attention for their ability to act as an amide bond bioisotere to improve pharmacokinetic properties. Herein we present a tandem amidine installation and subsequent cyclization with an adjacent ester to yield (4H)-imidazolone products. By using amino acid building blocks, we can access the first examples of alpha-chiral imidazolones which have been previously inaccessible. Additionally, our method is amenable to on-resin installation and can be integrated seamlessly into existing solid-phase peptide synthesis (SPPS) protocols. Finally, we show that imidazolones can act as \textit{cis}-amide bond surrogates to assist in pre-organizing linear peptides for head-to-tail macrocyclization. This work represents the first general approach to backbone and side-chain insertion of imidazolone bioisosteres at various positions in linear and cyclic peptides.

  • Design, synthesis, and applications of ring‐functionalized histidines in peptide‐based medicinal chemistry and drug discovery

    by Krishna K. Sharma, Amit Mahindra, Naina Sehra, Nitin Bagra, Shams Aaghaz, Rajesh Parmar, Gajanan K. Rathod, Rahul Jain

    Modified and synthetic α‐amino acids are known to show diverse applications. Histidine, which possesses numerous applications when subjected to synthetic modifications, is one such amino acid. The utility of modified histidines varies widely from remarkable biological activities to catalysis, and from nanotechnology to polymer chemistry. This renders histidine residue an important place in scientific research. Histidine is a well‐studied scaffold and constitutes the active site of various enzymes catalyzing important reactions in the biological systems. A rational modification in histidine structure with a distinctly developed protocol extensively changes its physical and chemical properties. The utilization of modified histidines in search of potent, target selective and proteostable scaffolds is vital in the development of bioactive peptides with enhanced drug‐likeliness. This review is a compilation and analysis of reported side‐chain ring modifications at histidine followed by applications of ring‐modified histidines in the synthesis of various categories of bioactive peptides and peptidomimetics.


  • A General Strategy to Install Amidine Functional Groups Along the Peptide Backbone

    by Emily A. O’bRien, Krishna K. Sharma, Jacob Byerly-Duke, Luis A. Camacho, Brett VanVeller

    Amidines are a structural surrogate for peptide bonds, yet have received considerably little attention in peptides due to limitations in existing methods to access them. The synthetic strategy developed in this study represents the first robust and general procedure for the introduction of amidines into the peptide backbone. We exploit and further develop the utility and efficiency of thioimidate protecting groups as a means to side-step reactivity that ultimately renders existing methods unsuitable for the installation of amidines along the main-chain of peptides. This work is significant because it describes a generally applicable path to access unexplored peptide designs and architectures for new therapeutics made possible by the unique properties of amidines.